Benzinga’s Top Ratings Upgrades, Downgrades For January 10, 2023
Upgrades Morgan Stanley upgraded the previous rating for Stem Inc (NYSE:STEM) from Equal-Weight to Overweight. In the third…
RBC Capital Downgrades Chemours to Sector Perform, Lowers Price Target to $33
RBC Capital analyst Arun Viswanathan downgrades Chemours (NYSE:CC) from Outperform to Sector Perform and lowers the price target from $35 to $33.
Chemours Q3 Adj. EPS $1.24 Beats $1.07 Estimate, Sales $1.78B Beat $1.68B Estimate
Chemours (NYSE:CC) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.07 by 15.89 percent. This is a 2.36 percent decrease over earnings of $1.27 per share from the same period
Morgan Stanley Maintains Equal-Weight on Chemours, Lowers Price Target to $33
Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $41 to $33.
Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30
Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $46 to $30.
Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce
Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero Therapeutics shares rose 7.3% to $2.37 on Friday.
UnitedHealth To Rally 24%? Here Are 5 Other Price Target Changes For Thursday
Raymond James raised the price target on UnitedHealth Group Incorporated (NYSE: UNH) from $620 to $635. Raymond James analyst John Ransom maintained the stock with a Strong Buy rating. UnitedHealth shares rose 0.1% to $512.50 in pre-market trading.
RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $35
RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $48 to $35.
Chemours, Alcoa And Other Big Losers From Wednesday
U.S. stocks closed lower with the Dow Jones dropping more than 500 points on Tuesday. Here is the list of some big stocks recording losses in the previous session.
RBC Capital Maintains Outperform on Chemours, Raises Price Target to $48
RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $44 to $48.